[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"enlarged-heart\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:enlarged-heart":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100462763",false,"NCT05305911","Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI","Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).","Inclusion Criteria:\n\n* Patients with their first STEMI (\\>18 years) who underwent successful primary PCI and able to give informed consent\n* At least mild LV dysfunction (LVEF \\\u003C 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI\n* Infarct size that is \\> 10% of LV mass\n* The presence of MVO that is \\> 10% of infarct size\n\nExclusion Criteria:\n\n* Contraindication to cardiac MRI\n* Life expectancy \\\u003C 1 year\n* Previous CABG or Valve Surgery\n* Previous STEMI\n* Pregnant or planning to become pregnant or lactating women\n* Cardiogenic shock (not resolved)\n* Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)\n* GFR\\\u003C30 ml\u002Fmin\u002F1.73m2 or end-stage renal disease on dialysis\n* Type 1 diabetes mellitus or history of diabetic ketoacidosis\n* Type I or II diabetes with insulin use\n* Prior intolerance of SGLT2 inhibitors\n* Current use of SGLT2 inhibitors (randomized patients only)\n* Contraindications to gadolinium","ALL","18 Years","75 Years",{"count":19,"type":20},81,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.",[26,27],"Heart Attack","Enlarged Heart",[29,30],"Dapagliflozin","Sodium Glucose Co-Transporter 2","RECRUITING","2024-10-03",{"date":34,"type":35},"2024-10-08","ACTUAL",{"date":37,"type":35},"2022-08-03",{"date":39,"type":20},"2028-12",{"name":41,"class":42},"Minneapolis Heart Institute Foundation","OTHER",""]